Semaglutide News and Research

Latest Semaglutide News and Research

Exploring the gut-brain-immune axis in neurodegeneration

Neurodegenerative diseases (NDs), such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS), represent a growing global health burden, particularly in aging populations.

28 Oct 2025

AI-powered app matches human-led programs in diabetes prevention

Researchers from Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health report that an AI-powered lifestyle intervention app for prediabetes reduced the risk of diabetes similarly to traditional, human-led programs in adults.

27 Oct 2025

Semaglutide protects the heart beyond weight loss, SELECT trial shows

Semaglutide lowered the risk of major adverse cardiovascular events across all body weight and waist circumference levels in people with overweight or obesity and cardiovascular disease. Early waist reduction explained only a third of this benefit, showing that semaglutide’s heart protection extends beyond fat loss.

26 Oct 2025

Semaglutide can offer important heart benefits that go beyond weight loss

A new analysis of the SELECT trial – the largest and longest clinical trial to date examining the cardiovascular benefits of semaglutide (a medication used to support weight loss and diabetes management) – confirms it also lowers the risk of major heart problems in people who are overweight or obese and already have heart disease, even if they don't have diabetes.

23 Oct 2025

A new car vs. health insurance? Average family job-based coverage hits $27K

With the federal shutdown entering its fourth week, spurred by a stalemate over the cost of health insurance for 22 million Americans on Affordable Care Act plans, a new report shows that over 154 million people with coverage through an employer also face steep price hikes — and that the situation is likely to get worse.

22 Oct 2025

Exercise can mitigate depression-like behaviors induced by high-fat, high-sugar diets

Researchers led by Professor Yvonne Nolan at University College Cork have identified specific metabolic pathways through which exercise counteracts the negative behavioral effects of consuming a Western-style cafeteria diet.

21 Oct 2025

GLP-1 drugs like Ozempic may slow how quickly alcohol hits the bloodstream

Preliminary study shows GLP-1 receptor agonists alter alcohol response, suggesting potential for reducing cravings and intoxication in obese individuals.

17 Oct 2025

New enzyme offers cleaner route to more stable diabetes and obesity drugs

Chemistry researchers at the University of Utah have uncovered an enzyme, dubbed PapB, that can "tie off" therapeutic peptides-protein-like drugs-into tight rings, a process known as macrocyclization.

16 Oct 2025

GLP-1 medications found to slow alcohol absorption and lessen intoxication

There's mounting evidence that popular drugs prescribed for diabetes management and weight loss - better known by trade names like Ozempic and Wegovy - could be effective in reducing alcohol use.

15 Oct 2025

In Mississippi, Medicaid coverage of weight loss drugs fails to catch on

April Hines has battled with her weight since she was a teenager. But in the past couple of years, she's fallen from 600 pounds to 385, and her blood pressure and blood sugar levels are down, too. "I'm not as fatigued as I used to be, and I've been able to go back to church," she said.

15 Oct 2025

GLP-1 therapeutics may have the potential to treat alcohol and drug addiction

A popular class of therapies for treating diabetes and obesity may also have the potential to treat alcohol and drug addiction, according to a new paper published in the Journal of the Endocrine Society.

9 Oct 2025

GLP-1 receptor agonists linked to altered patterns on FDG PET-CT scans

The growing use of GLP-1 receptor agonists may affect the interpretation of oncological FDG PET-CT scans, new research presented today at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM'25) has revealed.

7 Oct 2025

Study finds surge in the use of weight loss drugs among bariatric surgery patients

New research findings show a significant increase in the use of weight loss drugs among patients undergoing metabolic and bariatric surgery, signaling an evolution in the management of obesity and Type 2 diabetes.

3 Oct 2025

Prediabetes can go into remission without weight loss

Research shows up to 22% of prediabetic individuals achieve remission without weight loss, emphasizing metabolic health over weight loss in diabetes prevention.

2 Oct 2025

Study shows prediabetes remission does not always require weight loss

Remission of prediabetes can occur even without weight loss, protecting against type 2 diabetes in up to 22% of individuals. Metabolic improvements, healthier fat distribution, and enhanced β-cell function, not body weight change, drive this benefit.

30 Sep 2025

Cannabidiol shows promise for obesity and metabolic syndrome

Cannabidiol (CBD) shows promise in regulating appetite, glucose and lipid metabolism, and inflammation in preclinical models of obesity and metabolic syndrome. However, human evidence is still limited, highlighting the need for rigorous trials before clinical use.

29 Sep 2025

Scientists outline how future therapies could change type 1 diabetes care

Researchers writing in The Lancet review breakthroughs in type 1 diabetes treatment, from immunotherapies that delay onset to stem-cell β-cell replacement and automated insulin delivery. They stress that equitable access, validated surrogate endpoints, and scalable technologies are crucial for lasting impact.

24 Sep 2025

Georgia State scientist receives $25,000 grant to develop mechanisms for treating obesity

Chong Hyun Shin, a research associate professor in the Institute for Biomedical Sciences at Georgia State University, has received a $25,000 grant to develop mechanisms for treating obesity and obesity-related metabolic dysfunctions.

23 Sep 2025

Orforglipron pill improves heart and metabolic risk factors in trial

Patients taking an experimental oral GLP-1 drug lost significant weight and improved their heart and metabolic risk factors in a large, international, phase 3 clinical trial led by investigators at Weill Cornell Medicine, McMaster University, York University and other institutions.

22 Sep 2025

New quintuple agonist shows promise for treating obesity and type 2 diabetes

Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitor (single agonists such as semaglutide) and also dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists (dual agonists such tirzepatide).

21 Sep 2025